NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,461 | -99.8% | 462 | -99.4% | 0.00% | -99.7% |
Q2 2023 | $3,194,172 | +0.8% | 76,968 | +46.1% | 0.34% | -8.4% |
Q1 2023 | $3,167,514 | -14.2% | 52,669 | +4.6% | 0.37% | -18.5% |
Q4 2022 | $3,693,466 | +28311.3% | 50,354 | +29346.8% | 0.46% | +22650.0% |
Q3 2022 | $13,000 | +333.3% | 171 | +271.7% | 0.00% | – |
Q2 2022 | $3,000 | -25.0% | 46 | -9.8% | 0.00% | -100.0% |
Q1 2022 | $4,000 | +300.0% | 51 | +410.0% | 0.00% | – |
Q4 2021 | $1,000 | -90.0% | 10 | -88.9% | 0.00% | -100.0% |
Q3 2021 | $10,000 | -68.8% | 90 | -37.1% | 0.00% | -57.1% |
Q2 2021 | $32,000 | +88.2% | 143 | +10.0% | 0.01% | +75.0% |
Q1 2021 | $17,000 | -5.6% | 130 | +23.8% | 0.00% | 0.0% |
Q4 2020 | $18,000 | +63.6% | 105 | +5.0% | 0.00% | +33.3% |
Q3 2020 | $11,000 | +175.0% | 100 | +33.3% | 0.00% | +200.0% |
Q2 2020 | $4,000 | – | 75 | – | 0.00% | – |
Q4 2018 | $0 | – | 0 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |